Navigation Links
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
Date:5/6/2009

CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bordeaux. The contract covers the development, production and marketing of a paediatric beta-blocker for the treatment of severe infantile haemangioma with the intention of obtaining NDA-approval (New Drug Application) both for Europe and the USA. Patents were also applied for in this indication.

The efficacy of beta-blockers on haemangioma was discovered by Dr. Christine Leaute- Labreze, dermatologist in Pr. Alain Taieb's department in Bordeaux. "Effectiveness of this treatment has been demonstrated in several hundred children throughout the world. Rigorous clinical trials are, however, yet to be conducted to ascertain the efficacy and tolerance of this new therapeutic strategy, hence this agreement with Pierre Fabre Dermatologie, which would ensure safety and availability of the treatment."

This therapeutic breakthrough has been widely talked about, not only during scientific conferences but also through professional and general-interest press.

"This is a major discovery that will bring true therapeutic advance to patients affected by this highly apparent disease, which can be very severe and can have a strong impact on their quality of life and that of their parents. For this reason, we are highly honoured to have signed this agreement with the University of Bordeaux on severe haemangioma," specifies Jacques Fabre, General Manager of Pierre Fabre Dermocosmetique.

About haemangioma:

Infantile haemangioma refers to a vascular tumour highly prevalent in infants, with a 10% concurrency rate. Haemangioma occurs in the first months of life and is located on the face in 60% of cases
'/>"/>

SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
2. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
3. Evotec Starts Phase II in Smoking Cessation with EVT 302
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014  FlexTech Alliance ... for flexible, printed product demonstrators (demos) and a ... RFP process with pre-proposals due on October 22, ... Funds for proposals ultimately selected are provided by ... a significant cost share by the proposing organization. ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 Bioptigen ... deep imaging OCT system for the optical device metrology ... EnvisuTM S4410 SDOCT for Contact Lens Metrology ... standard and high complexity contact lens, IOL structures, and ... of a complete contact lens immersed in a hydration ...
(Date:9/15/2014)... 15, 2014 Applied Silicone Corporation, ... for the medical device and critical healthcare market, ... the implantable medical device market. The Dual ... delivering a silicone gel with improved fracture resistance, ... technology consists of two crosslinked networks working in ...
(Date:9/15/2014)... Hydro Dynamics, Inc. (HDI) of ... it will be partnering with Proteaf Technologies (Proteaf) ... for implementing its Shock Wave Power Reactor (SPR) ... Continuous flow chemistry through process intensification has been ... markets for decades. The continuous chemistry has ...
Breaking Biology Technology:FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2
... Sector, TROY, Mich., Nov. 10 Automation ... data from its,Fourth Annual Technology Industry Report: Driving ... on Wednesday, Nov. 12 at the,Troy Marriott. The ... regarding Automation Alley,s rapidly growing presence in the,life ...
... -- China Medicine,Corporation (OTC Bulletin Board: CHME) ... and distributor of prescription and over the ... supplements, and medical devices and medical formulations, ... call at 9:00 a.m. Eastern Time,on Thursday, ...
... The West Michigan Science,& Technology Initiative and ... a new medical device company, TransCorp, Inc. TransCorp ... Technology offices in,Grand Valley State University,s Cook-DeVos Center ... and commercialize novel surgical instruments,and implants. Other participants ...
Cached Biology Technology:Automation Alley Releases Report on State of Southeast Michigan's Technology Economy 2Automation Alley Releases Report on State of Southeast Michigan's Technology Economy 3China Medicine Announces Conference Call to Discuss Third Quarter 2008 Results 2West Michigan's Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures 2
(Date:9/15/2014)... lowland tapir populations may continue to drop in French ... the Office National de la Chasse et de la ... Global reviewed data retrieved from camera traps in the ... compared this data to current harvest rates in the ... in French Guiana," said Matthias Tobler, a scientist with ...
(Date:9/15/2014)... INDIANAPOLIS -- Adding a common epilepsy drug to a ... fewer side effects. Moreover, the combination can reduce the ... to a team of pain researchers at Indiana University. ... patients with neuropathic pain, a difficult-to-treat condition often felt ... tissue damage. , "There is a huge unmet need ...
(Date:9/15/2014)... a vital source of energy for both plants and ... way into the cell could lead to the design ... in the amount of fruits and vegetables farmers are ... one of these "pathways" into the cell by piecing ... strand of spider silk. , To determine the size, ...
Breaking Biology News(10 mins):IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3
... diabetes during pregnancy is directly controlled by serotonin, a ... a neurotransmitter, and is influenced by the amount of ... to new findings of an international team led by ... to simple dietary solutions and possible therapeutics for the ...
... rich? Smithsonian researchers have new evidence that the answer ... to a study published in the journal, Nature ., ... not grow and survive well under their mothers or other ... fellow at the University of WisconsinMilwaukee and the Smithsonian Tropical ...
... available in Spanish . , At a time ... Service (ARS)-funded scientists have contributed to a limited but growing ... cognitive function. Cognitive function is measured by the ... use available information for activities of daily life. Alzheimer,s disease, ...
Cached Biology News:Gestational diabetes linked to serotonin and dietary protein 2Gestational diabetes linked to serotonin and dietary protein 3Biodiversity's holy grail is in the soil 2Vitamin D and mental agility in elders 2
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... The CultureWell cell culture chambered ... cultured cells for staining and ... medical-grade silicone gaskets with standard ... sterile and ready to use. ...
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
...
Biology Products: